<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978403</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2019-002</org_study_id>
    <nct_id>NCT03978403</nct_id>
  </id_info>
  <brief_title>A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers</brief_title>
  <official_title>A Randomized Open-label Four-way Crossover Study of Pharmacokinetics, Safety, and Tolerability of 3 Formulations of M207 3.8 mg on the Upper Arm for 30 Minutes With Intranasal Zolmitriptan 2.5 mg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized, four-way crossover study. Subjects will&#xD;
      receive the four study treatments once, followed by in-clinic monitoring and extensive&#xD;
      pharmacokinetic analysis. Dosing occurs ~48 hours apart from patch application, in randomized&#xD;
      order. Subjects will have final assessment and be dismissed from the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, randomized, four-way crossover study. Each subject will&#xD;
      receive each of the four study treatments once, followed by in-clinic monitoring and&#xD;
      extensive blood sample collection for pharmacokinetic analysis.&#xD;
&#xD;
      Dosing will occur approximately 48 hours apart from the time of patch application, until&#xD;
      completion of dosing in randomized order per the treatment sequence schedule. Plasma samples&#xD;
      from the dosing days will be sent to the analytical laboratory for analysis and tolerability&#xD;
      for each of the dose levels will be summarized.&#xD;
&#xD;
      After completion of the four dosing days, subjects will be assessed one final time and&#xD;
      dismissed from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects are randomized to receive one of four treatment sequences of four open-label treatments 48 hours apart.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes; 2, 4 , 8, 12, and 24 hours post-dose</time_frame>
    <description>maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>48 hours</time_frame>
    <description>Subjects with treatment emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes; 2, 4 , 8, 12, and 24 hours post-dose</time_frame>
    <description>Time to maximum concentration</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>ABDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M207 3.8 mg &quot;Sled&quot; (two 1.9 mg patches made on a &quot;Sled&quot; coater, foil pouches)</intervention_name>
    <description>M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a &quot;Sled&quot; coater and packaged in foil pouches</description>
    <arm_group_label>ABDC</arm_group_label>
    <arm_group_label>BCAD</arm_group_label>
    <arm_group_label>CDBA</arm_group_label>
    <arm_group_label>DACB</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M207 3.8 mg &quot;MACAP&quot; (two 1.9 mg patches made on a &quot;MACAP&quot; coater, foil cups)</intervention_name>
    <description>M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a &quot;MACAP&quot; coater and packaged in foil cups</description>
    <arm_group_label>ABDC</arm_group_label>
    <arm_group_label>BCAD</arm_group_label>
    <arm_group_label>CDBA</arm_group_label>
    <arm_group_label>DACB</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M207 3.8 mg &quot;MiniMac&quot; (two 1.9 mg patches made on a &quot;MiniMac&quot; coater, foil cups</intervention_name>
    <description>M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a &quot;miniMac&quot; coater and packaged in foil pouches</description>
    <arm_group_label>ABDC</arm_group_label>
    <arm_group_label>BCAD</arm_group_label>
    <arm_group_label>CDBA</arm_group_label>
    <arm_group_label>DACB</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose</intervention_name>
    <description>Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose</description>
    <arm_group_label>ABDC</arm_group_label>
    <arm_group_label>BCAD</arm_group_label>
    <arm_group_label>CDBA</arm_group_label>
    <arm_group_label>DACB</arm_group_label>
    <other_name>Treatment D</other_name>
    <other_name>Zomig Nasal Spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women or men 18 to 50 years of age (inclusive)&#xD;
&#xD;
          2. Good general health with no clinically significant abnormalities as determined by&#xD;
             medical history, physical examination, complete blood count, blood chemistry,&#xD;
             urinalysis, and ECG.&#xD;
&#xD;
          3. Negative urine drug and alcohol screens and negative serum pregnancy tests (for female&#xD;
             subjects) at screening and admission/baseline visit.&#xD;
&#xD;
          4. Consent of female subjects to use a medically effective method of contraception&#xD;
             throughout the entire study period and for 30 days after the subject completes the&#xD;
             study. Medically effective methods of contraception that may be used by the subject&#xD;
             include abstinence, use of diaphragm and spermicide, intrauterine device (IUD), rings,&#xD;
             condom and vaginal spermicide, hormonal contraceptives (subjects must be stable on&#xD;
             hormonal contraceptives for at least 3 months prior to screening), surgical&#xD;
             sterilization (hysterectomy, bilateral tubal ligation, hysteroscopic sterilization)&#xD;
             and post-menopausal (≥ 2 years of amenorrhea).&#xD;
&#xD;
          5. Ability to read, understand, and provide written informed consent that they understand&#xD;
             the purpose of the study and procedures required for the study before enrolling in the&#xD;
             study, and willingness to comply with all study procedures and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of significant history of hepatic, reproductive, gastrointestinal, renal,&#xD;
             bleeding, or hematological disorders including coagulation, pulmonary, neurological,&#xD;
             respiratory, endocrine, or cardiovascular system abnormalities (especially&#xD;
             hypertension, peripheral vascular disease, coronary artery disease, transient ischemic&#xD;
             attacks, or cardiac rhythm abnormalities), psychiatric disorders, acute infection, or&#xD;
             other conditions that would interfere with study participation or with the absorption,&#xD;
             distribution, metabolism, or excretion of drugs.&#xD;
&#xD;
          2. Presence of three or more of the following CAD risk factors for cardiovascular&#xD;
             disease:&#xD;
&#xD;
             A. Current tobacco use (subjects who have smoked within 30 days of screening)&#xD;
&#xD;
             B. Hypertension (systolic BP &gt; 140 or diastolic BP &gt; 90) or receiving&#xD;
             anti-hypertensive medication for treatment of hypertension&#xD;
&#xD;
             C. Hyperlipidemia - LDL &gt; 159 mg/dL and/or HDL &lt; 40 mg/dL (or on prescribed&#xD;
             anti-cholesterol treatment)&#xD;
&#xD;
             D. Family history of premature coronary artery disease (CAD) (&lt; 55 years of age in&#xD;
             male first-degree relatives or &lt; 65 years of age in female first degree relatives)&#xD;
&#xD;
             E. Diabetes mellitus&#xD;
&#xD;
          3. Any contraindication to zolmitriptan administration including:&#xD;
&#xD;
               -  History of coronary artery disease or coronary vasospasm&#xD;
&#xD;
               -  Symptomatic Wolf-Parkinson-White syndrome or other cardiac accessory conduction&#xD;
                  pathway disorders&#xD;
&#xD;
               -  History of stroke, transient ischemic attack, or hemiplegic or basilar migraine&#xD;
&#xD;
               -  Peripheral Vascular Disease&#xD;
&#xD;
               -  Ischemic bowel disease&#xD;
&#xD;
               -  Hypertension (greater than or equal to 140/90 mmHg at either the screening or&#xD;
                  admission/baseline visit&#xD;
&#xD;
               -  Any history of hepatic impairment defined as alanine transaminase &gt; 150 U/L,&#xD;
                  aspartate aminotransferase &gt; 130 U/L or bilirubin &gt; 2 times the upper limit of&#xD;
                  normal&#xD;
&#xD;
          4. History of contact dermatitis or known dermatological disorders that would interfere&#xD;
             with the study procedures or assessments&#xD;
&#xD;
          5. Planned participation in activities which cause inflammation, irritation, sunburn,&#xD;
             lesions, or tattoos at the intended application sites from 2 weeks prior to dosing&#xD;
             through their last day of study participation&#xD;
&#xD;
          6. Use of any prescription anticoagulant within 1 month prior to the first dose&#xD;
&#xD;
          7. Use of prescription and over the counter medications within one week of dosing other&#xD;
             than the following:&#xD;
&#xD;
               -  Hormone Replacement Therapy (HRT)&#xD;
&#xD;
               -  Birth control pills, patches, IUD, rings, injections, or implants (all hormonal&#xD;
                  contraceptives) are allowed provided the dose has been stable for at least three&#xD;
                  months prior to screening and may be continued throughout the study&#xD;
&#xD;
               -  Proton Pump Inhibitors (PPIs)&#xD;
&#xD;
               -  Antihistamines&#xD;
&#xD;
               -  Intermittently used NSAIDS&#xD;
&#xD;
               -  Acetaminophen if medically necessary (not more than 1000 mg/day)&#xD;
&#xD;
               -  Exceptions may be allowed on a case by case basis&#xD;
&#xD;
          8. Subject has a known allergy or sensitivity to zolmitriptan or its derivatives or&#xD;
             formulations&#xD;
&#xD;
          9. Subject has a known allergy or sensitivity to tapes or adhesives&#xD;
&#xD;
         10. Use of any other investigational compound within 30 days of planned study drug dosing&#xD;
&#xD;
         11. Current use or history of drug and/or alcohol abuse within 6 months of screening and&#xD;
             deemed to be clinically significant by the investigator&#xD;
&#xD;
         12. History of nasal pathology (e.g., polyps) or abnormal nasal exam deemed to be&#xD;
             clinically significant by the investigator&#xD;
&#xD;
         13. Body Mass Index (BMI) lower than 18 kg/m2 or greater than 35 kg/m2&#xD;
&#xD;
         14. If, in the opinion of the investigator, the subject is not suitable for the study&#xD;
&#xD;
         15. Any positive urine drug screen result or alcohol test&#xD;
&#xD;
         16. Subject currently smokes or is a nicotine a user&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Kellerman, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Zosano Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <results_first_submitted>October 19, 2021</results_first_submitted>
  <results_first_submitted_qc>October 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2021</results_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy</keyword>
  <keyword>Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03978403/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03978403/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABDC</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
        </group>
        <group group_id="P2">
          <title>BCAD</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
        </group>
        <group group_id="P3">
          <title>CDBA</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
        </group>
        <group group_id="P4">
          <title>DACB</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABDC</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
        </group>
        <group group_id="B2">
          <title>BCAD</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
        </group>
        <group group_id="B3">
          <title>CDBA</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
        </group>
        <group group_id="B4">
          <title>DACB</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="9.69"/>
                    <measurement group_id="B2" value="42.2" spread="4.36"/>
                    <measurement group_id="B3" value="35.3" spread="10.09"/>
                    <measurement group_id="B4" value="39.5" spread="9.87"/>
                    <measurement group_id="B5" value="38.7" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.153" spread="3.9165"/>
                    <measurement group_id="B2" value="27.118" spread="3.1446"/>
                    <measurement group_id="B3" value="26.523" spread="4.8929"/>
                    <measurement group_id="B4" value="27.242" spread="2.6340"/>
                    <measurement group_id="B5" value="27.009" spread="3.5044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>maximum observed plasma concentration</description>
        <time_frame>pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes; 2, 4 , 8, 12, and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>M207 3.8 mg (Sled)</title>
            <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches</description>
          </group>
          <group group_id="O2">
            <title>M207 3.8 mg (MACAP)</title>
            <description>B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups</description>
          </group>
          <group group_id="O3">
            <title>M207 3.8 mg (MiniMac)</title>
            <description>C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups</description>
          </group>
          <group group_id="O4">
            <title>Zolmitriptan 2.5 mg (Intranasal)</title>
            <description>D: Zolmitriptan intranasal 2.5 mg/0.1 mL single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>maximum observed plasma concentration</description>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11670" spread="30.7"/>
                    <measurement group_id="O2" value="9861" spread="93.6"/>
                    <measurement group_id="O3" value="11680" spread="66.3"/>
                    <measurement group_id="O4" value="3705" spread="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Subjects with treatment emergent adverse events</description>
        <time_frame>48 hours</time_frame>
        <population>Subjects who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>M207 3.8 mg (Sled)</title>
            <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches</description>
          </group>
          <group group_id="O2">
            <title>M207 3.8 mg (MACAP)</title>
            <description>B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups</description>
          </group>
          <group group_id="O3">
            <title>M207 e.8 mg (MiniMac)</title>
            <description>C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups</description>
          </group>
          <group group_id="O4">
            <title>Zolmitriptan 2.5 mg (Intranasal)</title>
            <description>D: Zolmitriptan intranasal 2.5 mg/0.1 mL single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Subjects with treatment emergent adverse events</description>
          <population>Subjects who received treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time to maximum concentration</description>
        <time_frame>pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes; 2, 4 , 8, 12, and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>M207 3.8 mg (Sled)</title>
            <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches</description>
          </group>
          <group group_id="O2">
            <title>M207 3.8 mg (MACAP)</title>
            <description>B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups</description>
          </group>
          <group group_id="O3">
            <title>M207 3.8 mg (MiniMac)</title>
            <description>C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups</description>
          </group>
          <group group_id="O4">
            <title>Zolmitriptan 2.5 mg (Intranasal)</title>
            <description>D: Zolmitriptan intranasal 2.5 mg/0.1 mL single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to maximum concentration</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.529" lower_limit="0.34" upper_limit="0.76"/>
                    <measurement group_id="O2" value="0.577" lower_limit="0.04" upper_limit="0.79"/>
                    <measurement group_id="O3" value="0.575" lower_limit="0.33" upper_limit="0.77"/>
                    <measurement group_id="O4" value="2.000" lower_limit="0.56" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 days total, 48 hours per intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>M207 3.8 mg (Sled)</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;Sled&quot; coater and packaged in foil pouches</description>
        </group>
        <group group_id="E2">
          <title>M207 3.8 mg (MACAP)</title>
          <description>B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;MACAP&quot; coater and packaged in foil cups</description>
        </group>
        <group group_id="E3">
          <title>M207 3.8 mg (MiniMac)</title>
          <description>C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a &quot;miniMac&quot; coater and packaged in foil cups</description>
        </group>
        <group group_id="E4">
          <title>Zolmitriptan 2.5 mg (Intranasal)</title>
          <description>D: Zolmitriptan intranasal 2.5 mg/0.1 mL single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal ditension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal tenesmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal sstiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Paraesthesea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Don Kellerman, Sr. VP, Clinical Development and Medical Affairs</name_or_title>
      <organization>Zosano Pharma Corporation</organization>
      <phone>+1 (510) 745-4004</phone>
      <email>dkellerman@zosanopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

